HC Wainwright & Co. Reiterates Buy on Apellis Pharmaceuticals, Maintains $100 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on Apellis Pharmaceuticals (NASDAQ:APLS) and maintained a $100 price target.
July 18, 2023 | 10:16 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Apellis Pharmaceuticals has received a reiterated 'Buy' rating and a maintained $100 price target from HC Wainwright & Co.
The reiterated 'Buy' rating and maintained $100 price target by HC Wainwright & Co. indicates a positive outlook for Apellis Pharmaceuticals. This could potentially attract investors, driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100